Company Overview
- Headquarters
- San Diego, US, US
- Website
- genelux.com
- Employees
- 26
- Industry
- BioTech/Drugs
Financials & Stats
Revenue
$10B
Who is Genelux
Genelux Corporation is a late clinical-stage biotechnology company headquartered in the United States. Currently employing 26 individuals, the company is publicly traded on the NASDAQ under the ticker symbol GNLX. Genelux focuses on developing innovative treatments for patients battling challenging solid tumors. The company's core technology, the ChoiceTM Discovery Platform, has yielded over 500 variations of the vaccinia virus, which serves as the basis for their oncolytic immunotherapies. Their lead product candidate, Olvi-Vec, is currently undergoing a Phase 3 clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Olvi-Vec is also in development for other cancer types, including Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer. Genelux is dedicated to creating a pipeline of next-generation oncolytic immunotherapies designed to deliver a complete range of tumor neo-antigens, stimulating a personalized immune response in patients with aggressive and/or hard-to-treat solid tumors. For more details about Genelux's investigational products, clinical trials, or to stay updated on their progress, visit their website at genelux.com. You can also connect with them on Twitter (@Genelux_Corp) and Facebook (@Genelux).
Genelux Industry Tags
Companies Similar to Genelux
Analyze industry trends and opportunities by examining competitors and companies comparable to Genelux, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
Company Name | Revenue | Number of Employees | Location | Founded in |
---|---|---|---|---|
10M | 18 | Arizona City, AZ | 1998 | |
10M | 9 | San Diego, CA | ||
10M | 6 | Campbell, CA | 2011 | |
10M | 2 | Torrington, WY | ||
10M | 1 | San Diego, CA | 2016 |